Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer DOI Creative Commons
Xinda Yang, Chuansheng Xu, Yong Zeng

и другие.

Advanced Science, Год журнала: 2025, Номер unknown

Опубликована: Май 28, 2025

Abstract Pyroptosis has attracted significant attention for its role in cancer chemotherapy and immunotherapy. However, few drugs have been reported to induce pyroptosis via the Caspase‐3/gasdermin E (GSDME) pathway. Herein, three novel Pt IV prodrugs, MRP , DRP HRP are rationally designed by conjugating DNA methyltransferase (DNMT) inhibitor (RG108) and/or histone deacetylase (HDAC) (PhB) center. These prodrugs can be easily reduced cisplatin ( CDDP ) due high glutathione (GSH) levels tumors, liberating coordinated ligands. Released RG108 reactivates GSDME gene reduces low GSDME‐expressing tumor cells. Meanwhile, PhB‐induced chromatin loosening enhances CDDP‐DNA binding, which not only increases Caspase‐3 expression, but also upregulates GSDME. demonstrates superior ability suppress growth metastasis while reducing systemic toxicity compared with . By reactivating chromatin, effectively boosts cell exhibits most pronounced anticancer performance. findings highlight ’s potential as a therapeutic agent triple‐negative breast (TNBC) offer innovative strategies combining To best of current knowledge, this is first report platinum complexes inducing Caspase‐3/GSDME pathway

Язык: Английский

Harnessing donor cyclization strategy: Converting type II to type I photosensitizers and enhancing AIE performance for NIR-II FL/MR imaging-guided photodynamic therapy under hypoxia condition DOI

Chonglu Li,

Jie Li,

Yida Pang

и другие.

Chemical Engineering Journal, Год журнала: 2024, Номер unknown, С. 155471 - 155471

Опубликована: Сен. 1, 2024

Язык: Английский

Процитировано

4
NIR-II imaging guided on-site size variable clustered nanosystem to potentiate sonodynamic therapy in deep-seated tumors DOI
Qi Yu, Yujing Zhou, Qin Zhang

и другие.

Biomaterials, Год журнала: 2025, Номер 322, С. 123381 - 123381

Опубликована: Апрель 29, 2025

Язык: Английский

Процитировано

0
Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer DOI Creative Commons
Xinda Yang, Chuansheng Xu, Yong Zeng

и другие.

Advanced Science, Год журнала: 2025, Номер unknown

Опубликована: Май 28, 2025

Abstract Pyroptosis has attracted significant attention for its role in cancer chemotherapy and immunotherapy. However, few drugs have been reported to induce pyroptosis via the Caspase‐3/gasdermin E (GSDME) pathway. Herein, three novel Pt IV prodrugs, MRP , DRP HRP are rationally designed by conjugating DNA methyltransferase (DNMT) inhibitor (RG108) and/or histone deacetylase (HDAC) (PhB) center. These prodrugs can be easily reduced cisplatin ( CDDP ) due high glutathione (GSH) levels tumors, liberating coordinated ligands. Released RG108 reactivates GSDME gene reduces low GSDME‐expressing tumor cells. Meanwhile, PhB‐induced chromatin loosening enhances CDDP‐DNA binding, which not only increases Caspase‐3 expression, but also upregulates GSDME. demonstrates superior ability suppress growth metastasis while reducing systemic toxicity compared with . By reactivating chromatin, effectively boosts cell exhibits most pronounced anticancer performance. findings highlight ’s potential as a therapeutic agent triple‐negative breast (TNBC) offer innovative strategies combining To best of current knowledge, this is first report platinum complexes inducing Caspase‐3/GSDME pathway

Язык: Английский

Процитировано

0